Skip to main content

Table 1 Clinical and pathological variables in ClinicoMolecular Triad Classification of breast cancer in training and validation cohorts

From: A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis

  Training cohort (n= 149) Validation cohort (n= 2,487)
Variables CMTC-1, n(%) CMTC-2, n(%) CMTC-3, n(%) Pvalue CMTC-1, n(%) CMTC-2, n(%) CMTC-3, n(%) Pvalue
Total 45 (30.2) 65 (43.6) 39 (26.2)   803 (32.3) 794 (31.9) 890 (35.8)  
Age         
   < 50 15 (33.3) 18 (27.7) 17 (43.6) 2.51E-01 231 (39.1) 202 (34.9) 299 (43.6) 6.30E-03
   ≥ 50 30 (66.7) 47 (72.3) 22 (56.4)   360 (60.9) 377 (65.1) 386 (56.4)  
Size         
   ≤ 2 cm 23 (51.1) 21 (32.3) 11 (28.2) 5.62E-02 361 (54.7) 209 (32.5) 235 (32.4) 1.05E-20
   > 2 cm 22 (48.9) 44 (67.7) 28 (71.8)   299 (45.3) 434 (67.5) 490 (67.6)  
LN- 26 (59.1) 21 (32.3) 24 (61.5) 3.27E-03 490 (66.8) 436 (59.2) 498 (60.3) 4.37E-03
LN+ 18 (40.9) 44 (67.7) 15 (38.5)   243 (33.2) 301 (40.8) 328 (39.7)  
Grade         
   1 13 (28.9) 1 (1.5) 0 (0.0) 5.55E-13 270 (39.4) 81 (12.2) 29 (3.9) 3.47E-130
   2 27 (60.0) 30 (46.2) 6 (15.4)   342 (49.9) 339 (51.2) 220 (29.6)  
   3 5 (11.1) 34 (52.3) 33 (84.6)   74 (10.8) 242 (36.6) 495 (66.5)  
ER- 0 (0.0) 1 (1.5) 35 (89.7) 1.16E-27 69 (8.6) 45 (5.7) 584 (65.6) 2.60E-211
ER+ 45 (100) 64 (98.5) 4 (10.3)   734 (91.4) 749 (94.3) 306 (34.4)  
Her2+/TN         
   No 42 (93.3) 60 (92.3) 3 (7.7) 1.87E-22 715 (89.0) 668 (84.1) 238 (26.7) 1.45E-197
   Yes 3 (6.7) 5 (7.7) 36 (92.3)   88 (11.0) 126 (15.9) 652 (73.3)  
Recurrence         
   No 44 (97.8) 61 (93.8) 34 (87.2) 1.49E-01 595 (81.4) 423 (59.5) 486 (61.0) 1.99E-22
   Yes 1 (2.2) 4 (6.2) 5 (12.8)   136 (18.6) 288 (40.5) 311 (39.0)  
  1. CMTC = ClinicoMolecular Triad Classification; LN = lymph node status; ER = estrogen receptor; TN = triple-negative.